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a Case Report: pseudoangiomatous 
stromal Hyperplasia tumor 
presenting as a palpable Mass
Q. D. Vo1* , G. Koch1 , J. M. Girard1 , L. Zamora1 , Jean Bouquet de Jolinière2* ,  
F. Khomsi2 , A. Feki2 and H. M. Hoogewoud1
1 Department of Radiology, HFR Fribourg, Cantonal Hospital, Fribourg, Switzerland, 2 Department of Gynecology and 
Obstetrics, HFR Fribourg, Cantonal Hospital, Fribourg, Switzerland
We report a case of woman with a palpable lump on her left breast. On mammography, 
a huge mass located between the inner and the outer inferior breast quadrants of the 
left breast was found. The ultrasound examination realized later revealed a heteroge-
neous mass with smooth and lobulated borders. An MRI was also performed, showing 
an oval mass with heterogeneous areas of enhancement. Finally, a core biopsy under 
sonographic guidance revealed a pseudoangiomatous stromal hyperplasia of the breast.
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BaCKGRoUND
Pseudoangiomatous stromal hyperplasia (PASH) is a relatively common finding on histological 
examination and can be found in normal breasts. It presents rarely as a palpable lump. The main 
differential diagnosis on imaging is fibroadenoma and phyllode tumor. Histologically, it is important 
to differentiate PASH from a low-grade angiosarcoma. Management of PASH differs according to 
presentation and clinical symptoms. The main purpose of this article is to present imaging features 
and the management of PASH.
Case pReseNtatIoN
A 50-year-old woman reported a palpable mass in her left breast for few months associated with 
radiating pain in her left arm. Her medical history revealed no previous pregnancy, no previous 
pathology in the family, a tubal ligation with Pfannenstiel technique in Brazil in 1986, and a total 
hysterectomy with conservation of ovaries due to fibroids in 2011. The physical examination con-
firmed a palpable hard mass in the left breast located in the inferior quadrants. No palpable lymph 
nodes were noticed.
INVestIGatIoNs
On mammography (Figure  1), including a craniocaudal and a mediolateral oblique view of the 
breasts, a huge well-demarcated mass with lobulated borders containing tiny calcifications in the left 
breast, corresponding to BI-RADS category 3 was found. This mass was located between the inner 
and the outer inferior quadrants. An additional ultrasound (Figure 2) was realized and demonstrated 
a well-defined heterogeneous lobulated hypoechoic mass measuring 5.17 cm × 1.74 cm. In order to 
confirm the benign nature of the lesion, an MRI scan (Figure 3) was performed, which demonstrated 
FIGURe 3 | MRI showing the mass on the left breast with lobulated 
appearances. On T2-weighted MR image with fat saturation (a), the lesion 
demonstrates a heterogeneous appearance with areas of low and high 
signal. On T1-weighted MR image (B), the lesion shows a more 
homogeneous appearance with a hyposignal. On T1-weighted MR image 
with gadolinium and fat saturation (C), the mass demonstrates a 
heterogeneous enhancement, with a polylobulated appearance. No 
lymphadenopathies are seen.
FIGURe 2 | Ultrasound of the left breast centered on the palpable 
lump showing an oval, heterogeneous lesions with smooth borders.
FIGURe 1 | Mammography performed with craniocaudal (a) and 
mediolateral oblique (B) incidences of the left breast shows a huge 
well-defined mass located between the inner and the outer inferior 
quadrants, with no suspicious features.
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a huge mass with cystic components presenting a hypointense 
signal on T1- and T2-weighted images and a heterogeneous 
enhancement on post-contrast sequences.
DIFFeReNtIaL DIaGNosIs
According to the clinical results of examination and imaging, 
the main differential diagnosis was a fibroadenoma and phyllode 
tumor.
MaNaGeMeNt
A core biopsy under ultrasound guidance was performed. The 
specimen revealed a pseudo vascular proliferation of mammary 
stroma delineated by endothelial cells with canalar hyperplasia 
without atypia (Figure 4). These findings were compatible with a 
PASH. After discussion with the patient, it was decided to follow-
up the lesion.
FIGURe 4 | Microscopic examination showing a pseudo vascular proliferation delineated with endothelial cells with canalar hyperplasia without 
atypia, without invasion of parenchyma.
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DIsCUssIoN
Pseudoangiomatous stromal hyperplasia is a benign proliferative 
breast disease that was first described by Vuitch et al. (1). This 
lesion is characterized by a dense, collagenous proliferation of 
mammary stroma, forming inter-anastomosing capillary-like 
spaces. It is thought that hormonal factors play an important role 
in PASH (2). According to Anderson et al., this lesion represents 
an important hyper-response to progesterone and estrogen (3). 
PASH is a common histological finding in breast biopsy specimens 
and can also be found in a normal breast that is in association 
with proliferative or non-proliferative fibrocystic changes (4), but 
it is rarely a symptomatic lesion. Clinically, PASH can presents as 
a solitary firm, mobile, palpable lump, or as multifocal nodules in 
60% of cases (1, 2, 4–6) or can be discovered incidentally on imag-
ing. PASH can be found in teenage girls as well as in postmeno-
pausal women with or without hormonal therapy replacement (6, 
7). It is important to recognize this entity because it can be easily 
confused with others benign tumors, such as fibroadenoma, phyl-
lode tumor, or with malignant tumors, such as angiosarcoma (1, 
6). Unfortunately, imaging features of PASH are non-specific (4). 
On mammography, the most common appearance described is a 
well-defined, uncalcified mass, with regular borders. Spiculated 
borders, suspicious borders, and architectural distortion can also 
be seen but are uncommon (8–10). On ultrasound, PASH tends 
to be an oval, round hypoechoic mass or can presents as a het-
erogeneous mass with cystic areas (8). According to Cohen et al. 
(4), when a focal lesion with well-defined borders, containing no 
calcifications on mammography or a well-defined hypoechoic 
mass on ultrasound is seen, PASH can be considered and included 
in the differential diagnosis.
Clinically and on imaging, the differential diagnosis include 
fibroadenoma, especially in young patient and a phyllode tumor 
in older women (1, 5, 7). Histologically, PASH can be very similar 
to low-grade angiosarcoma.
Definitive diagnosis is based on histology (11–13). As men-
tioned earlier, PASH can have very similar histological features 
as low-grade angiosarcoma. But unlike low-grade angiosarcoma, 
PASH lacks of invasive features (14) and contains no necrosis, 
mitoses, and no destruction of mammary epithelial structures (1).
Management of PASH depends on presentation. When PASH 
is incidentally discovered or when it is asymptomatic, it can be 
followed up yearly by ultrasound or mammography for a period 
of 36 months (11, 12, 15). Surgical procedures are indicated for 
symptomatic lesion with mechanical complaints, pain or appre-
hension for an alternative malignant lesion (11, 12).
etHICs stateMeNt
Written informed consent was obtained from the patient prior 
to presenting the case.
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